281 patients who were diagnosed as MDR-TB by Department of Chest disease and Tuberculosis hospital, Hanamkonda were enrolled in the study over a period of January 2016 to may 2018. Detection and monitoring of ADR was done by interviewing patient and reviewing laboratory tests on monthly basis till their ATT continued. Patients were instructed to report any sign and symptoms they come across during the treatment period. A total of 317 ADRs were detected, documented, assessed and reported during the study period. The causality assessment of ADRs reveled that most of the ADRs were “possible” in nature. Assessment of severity of the suspected ADRs revealed that 35.78% of suspected ADRs were mild and 51.38% of ADRs were moderate in severity. Early detection, management and reporting of ADRs remain key factors in the management of MDR-TB with remarkable relevance to prevent emergence threat of global MDR-TB.

Keywords: Multi drug resistant tuberculosis, adverse dug reaction, anti tubercular therapy.

1. WHO Global Tuberculosis Report 2016
2. Honnaddi UC, Honnaddi MU, Tharangini SR, Hossain T, So­mani R. Adverse Drug Reactions to First Line Anti-Tubercular Drugs-A Pharmacovigilance Study. IJPR, 2016; 6(2):51-54.
3. Mishra S, Jena M, Jena B, Mishra SS. A study of Anti-tubercu­lar drug induced adverse drug reactions in patient’s pulmonary medicine department of a tertiary care teaching hospital. Int J Pharm Sci Rev Res, 2013; 21(2):308-311.
4. Kinjal P, Mira D, Samidh S, Jigar P, Kapadia J, Dikshit R. An analysis of serious adverse drug reactions at a tertiary care teaching hospi­tal. Perspect Clin Res 2016; 7(4):81-86.
5. Ramanath KV, Ramesh.S. A study on assessment of Adverse Drug Reactions in Tuberculosis patients. American Journal of Pharmtech Research, 2012; 2(2):584-592.
6. KapadiaVishakha, K. and Tripathi Sanjay, B. (2013) Analysis of 63 Patients of MDR TB on DOTS Plus regimen: An LG Hospital, TB Unit, Ahmedabad Experience. Gujarat Medical Journal, 68, 52-57.
7. Patil SV, Bhagwat RV, Mohite RV, Barphe SS. Profile of adverse drug reactions in multiple drug resistant tuberculosis patients at drug resistant-tuberculosis center - Miraj, Maharashtra. Int J Med Sci Public Health 2017;6(5):853-858.
8. Rathod KB, Borkar MS, Lamb AR, Suryavanshi SL, Surwade GA, Pandey VR. Adverse events among patients of multi drug resistant tuberculosis receiving second line anti TB treatment. Int J Sci Rep 2015;1(6):253-7
9. Vardhan A, Dr. Gupta A, Dr. Sehgal V.K, Dr. Kansal AP, and Dr. K. Sudesh Adverse drug reactions due to anti tubercular drugs in patients of multidrug resistant tuberculosis in Rajindra hospital Patiala World Journal of Pharmaceutical Research Vol 5, Issue 4, 2016. 1206.
10. Akshata JS, Chakrabarthy A, Swapna R, Buggi S, Somashekar M. Adverse drug reactions in management of multi drug resistant tuberculosis, in tertiary chest institute. Journal of Tuberculosis Research. 2015 Apr 16;3(02):27.
11. Neeta PN, Prashanth N, Ramaprasad G, Gangadhar Goud T, Sameena ARB. A study on outcome of standardized treatment in multidrug resistance tuberculosis patients. Int J Community Med Public Health 2016;3:257-63.
12. Zala AC, Manvar R, Patel D, Patel D, Gamit N. A prospective-observational study to assess the prevalence of adverse drug reactions in MDR-TB patients at tertiary care hospital in India. American Journal of Pharmacology and Pharmacotherapeutics.2015; 2(4):112-9.
13. Shinde MP, Halasawadekar NR, Ramanand SJ, Pore SM, Ramanand JB, Patil PT, Kumbhar AV. A study of adverse drug reactions in patients receiving treatment for multi-drug resistant tuberculosis. International Journal of Basic & Clinical Pharmacology. 2017 Jan 28;6(2):354-8.

G Nikhitha

Email: This email address is being protected from spambots. You need JavaScript enabled to view it., Mobile: 8179439290